抗白细胞介素6及其受体单克隆抗体治疗自身免疫病研究进展

摘要

白细胞介素6 (interleukin-6,IL-6)是调节免疫反应和炎性反应的多效性细胞因子,通过形成IL-6/IL-6受体(IL-6 receptor,IL-6R)/gp130复合体发挥生物学作用.因此,靶向抑制IL-6或IL-6R的单克隆抗体(单抗)可以用来治疗自身免疫病.随着包括IL-6/IL-6R抑制剂在内的多种生物制剂推向临床,新的问题也开始产生,如选用何种药物既可以改善病情又能避免严重不良反应.此文以抗IL-6单抗Sirukumab和抗IL-6R单抗Tocilizumab为代表,着重对这类药物治疗各种自身免疫病的有效性和安全性进行综述.%Interleukin-6 (IL-6) is a cytokine with a broad spectrum of effects on immune and inflammatory responses,whose biological function is transduced by the IL-6/interleukin 6 receptor (IL-6R)/gp130 complex.Monoclonal antibodies (mAb) targeting IL-6 or IL-6R can block signal transduction and therefore alleviate severity of autoimmune diseases.With varieties of biological agents including IL-6/IL-6R blockades becoming clinically available,new problems,such as which agent should be chosen to improve disease outcome and avoid severe adverse reaction,also arise.This review,focusing on Sirukumab (anti-IL-6 mAb) and Tocilizumab (anti-IL-6R mAb) as representative agents,discusses the efficacy and safety of anti-IL-6/IL-6R mAb as treatment for autoimmune diseases.